In In re Lipitor Antitrust Litigation, Judge Sheridan (District of New Jersey) found that the notion of “payment” in drug patent settlements extends beyond cash transfers to include non-cash conveyances. But the court required such a conveyance to be “converted to a reliable estimate of its monetary value” and ruled that non-cash deals should clear a heightened plausibility standard. The court also introduced a new test that was based on the False Claims Act and that significantly raised the bar facing plaintiffs.
In a brief filed last week on behalf of 48 professors and the American Antitrust Institute, Professor Michael Carrier and Steve Shadowen call on the Third Circuit to reverse this decision. They contend that the opinion undermines the Supreme Court’s ruling in FTC v. Actavis, the Third Circuit’s Lamictal decision, and pleading requirements articulated in Supreme Court and Third Circuit precedents. The brief also highlights allegations that typically survive a motion to dismiss, most notably the brand firm’s forgiveness of hundreds of millions of dollars facing the generic in separate litigation.
The Third Circuit will consider this case together with an earlier-filed appeal in the In re Effexor case, which also involved heightened pleading standards, in this case applied to a “no-authorized-generic” promise by which a brand promises not to introduce its own generic that would compete with the “true” generic.
Full content attached: Lipitor amicus brief 48 profs AAI
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI